Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer.

Matrix metalloproteinases (MMPs) are enzymes thought to be involved in tumor invasion. We hypothesized that MMP-2 and MMP-11 overexpression was associated with the aggressiveness of ovarian carcinoma. This study was performed on samples from 100 patients with stage III ovarian carcinomas treated surgically between 1990 and 2000. Immunohistochemical staining was performed on ovarian tumors and peritoneal implants using monoclonal antibodies. Overexpression was defined as more than 10% of cells expressing the marker. Multivariate analyses showed that only MMP-2 overexpression by cancer cells in peritoneal implants was associated with a significant risk of death by disease (hazard ratio, 2.65; 95% confidence interval, 1.41-4.97; P =.003). MMP-11 overexpression was not predictive of survival. These results suggest that MMP-2 overexpression by cancer cells in peritoneal implants and not in the primary ovarian cancer is predictive of ovarian cancer prognosis and more likely reflects the presence of particularly aggressive clones of cancer cells.

[1]  M. Dimopoulos,et al.  Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience , 2006, Oncology.

[2]  L. Seymour,et al.  A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. , 2006, Gynecologic oncology.

[3]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[4]  B. Nielsen,et al.  Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. , 2005, Carcinogenesis.

[5]  S. Bapat,et al.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.

[6]  J. Foidart,et al.  Membrane associated proteases and their inhibitors in tumour angiogenesis , 2004, Journal of Clinical Pathology.

[7]  A. Jayasurya,et al.  Metallothioneins in human tumors and potential roles in carcinogenesis. , 2003, Mutation research.

[8]  Dominique Trudel,et al.  An immunohistochemical study , 2013 .

[9]  R. Nahta,et al.  HER-2-targeted therapy: lessons learned and future directions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Ioanna Giannopoulou,et al.  Stromelysin-3 Protein Expression in Invasive Breast Cancer: Relation to Proliferation, Cell Survival and Patients’ Outcome , 2002, Modern Pathology.

[11]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[12]  J. Nesland,et al.  Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. , 2001, European journal of cancer.

[13]  E. Lengyel,et al.  Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. , 2001, Gynecologic oncology.

[14]  A. Gown,et al.  Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. , 2001, Gynecologic oncology.

[15]  L. Devy,et al.  New functions of stromal proteases and their inhibitors in tumor progression. , 2001, Surgical oncology clinics of North America.

[16]  H. Höfler,et al.  Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential , 2000, Virchows Archiv.

[17]  K. Shigemasa,et al.  Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. , 2000, International journal of oncology.

[18]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[19]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Têtu,et al.  Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. , 1998, Human pathology.

[21]  M. Duffy,et al.  High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma , 1996, International Journal of Cancer.

[22]  J. Foidart,et al.  Stromelysin-3 expression promotes tumor take in nude mice. , 1996, The Journal of clinical investigation.

[23]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[24]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[25]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[26]  J. Nesland,et al.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma , 2004, Clinical & Experimental Metastasis.

[27]  B. Shan,et al.  Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer. , 2002, Gynecologic oncology.

[28]  S. Silverberg.  Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[29]  L. Coussens,et al.  Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.

[30]  J. Brisson,et al.  Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[31]  Catherine,et al.  Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. , 1993, Cancer research.